Anika Therapeutics | ANIK - Beneficio Operativo

Precio De Mercado
14.57
Cambio Diario
0.29 2.03%
Mensual
13.92%
Anual
-3.89%
Q1 Expectativa
13.43




Beneficio Operativo Cambio Fecha
Abbott USD 2.25B 73M 2025-12
Agenus USD 14.4M 19.26M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Integra LifeSciences USD 66M 54.24M 2025-12
Intrexon USD -60.84M 26.62M 2024-06
J&J USD 5.59B 1.81B 2025-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
MacroGenics USD -12.1M 30.74M 2025-12
Merit Medical Systems USD 54.2M 11.58M 2025-12
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.7B 2.17B 2025-12
Smith & Nephew USD 440M 50M 2025-12
Stryker USD 1.97B 609M 2025-12
Surmodics USD -5.64M 276K 2024-09
Veracyte USD 24.63M 1.52M 2025-12
Xencor USD -53.63M 6.11M 2025-12
Zimmer Biomet Holdings USD 302.9M 35.4M 2025-12